Rezolute, Inc.

RZLT

Rezolute, Inc.

RZLT

Insider Sentiment (TTM):

Last Purchase:2026-03-30Last Sale:-Shares Purchased (TTM):138,299Shares Sold (TTM):0

Institutional Sentiment:

As of:2026-03-31Institutional Shares Owned:85,831,054Shares Outstanding:104,040,292Institutional Ownership Pct.:82.50%

Earnings Market Reaction:

Filing Date:2026-05-12Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	11	12	9	94	15	9	10	70	6	13	8	16
Marketable Securities Current	109	121	143	74	72	88	98	56	74	80	91	86
Prepaid Expense And Other Assets Current	2	2	3	3	2	2	2	2	2	3	4	3
Assets Current	122	135	155	171	89	99	110	129	82	96	103	105
Assets Noncurrent
Deposits Assets Noncurrent	2	2	3	3	3	3	2	2	2	0	0	0
Marketable Securities Noncurrent	-	-	-	-	2	9	10	0	2	3	8	16
Operating Lease Right Of Use Asset	1	1	1	1	1	2	2	2	2	2	2	2
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	0
Assets	125	139	159	175	95	112	123	133	88	102	113	124
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	3	4	3	6	7	3	2	5	3	4	2	3
Accrued Liabilities Curre…
Employee Related Liabilities Current	1	2	3	2	1	4	3	2	1	2	2	1
Operating Lease Liability Current	1	1	1	1	1	1	1	1	1	1	1	1
Liabilities Current	8	10	10	12	11	11	8	10	7	8	7	5
Liabilities Noncurrent
Embedded Derivative Fair Value Of Embedded Derivat…	0	0	0	0	0	0	0	0	0	0	0	0
Operating Lease Liability Noncurrent	0	1	1	1	1	1	1	2	2	2	2	2
Liabilities	9	11	11	13	12	12	10	12	17	10	9	8
Stockholders Equity
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	578	573	569	566	462	460	458	450	377	381	379	377
Accumulated Other Comprehensive Income Loss Net Of…	-0	0	0	-0	0	0	0	-0	-0	-0	-0	-0
Retained Earnings Accumulated Deficit	-461	-445	-422	-404	-379	-361	-345	-329	-306	-289	-276	-261
Stockholders Equity	117	128	147	162	83	100	113	121	71	92	104	116
Liabilities And Stockholders Equity	125	139	159	175	95	112	123	133	88	102	113	124
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Issued	0	0	0	0	0	0	0	0	0	0	0	0
Preferred Stock Shares Outstanding	-	-	-	-	-	-	-	-	0	0	0	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Common Stock Shares Authorized	165	165	165	165	165	165	100	100	100	100	100	100
Common Stock Shares Issued	96	96	91	87	61	61	55	53	40	40	37	37
Shares Outstanding	96	96	91	87	61	61	55	53	40	40	37	37

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2026	1.25%	-72.19%	-63.33%	-14.33%	-14.05%	-9.09%	28.79%	48.79%	43.03%	-	-	-
2025	-11.89%	-13.29%	-15.91%	-20.78%	-47.94%	-17.70%	20.71%	31.34%	59.95%	7.26%	39.56%	35.15%
2024	0.82%	12.31%	23.09%	74.31%	116.51%	203.67%	115.85%	55.85%	62.26%	-2.49%	15.77%	7.47%
2023	-	-	-	-	-	-	-	-	-	-31.23%	-35.48%	-47.94%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31	2024-12-31	2024-09-30	2024-06-30	2024-03-31	2023-12-31	2023-09-30	2023-06-30
Liquidity Ratios
Current Ratio	15.84	14.18	15.15	14.37	8.43	9.30	13.79	13.39	11.82	12.00	14.27	20.18
Quick Ratio	15.61	13.95	14.91	14.09	8.25	9.10	13.55	13.21	11.50	11.56	13.72	19.60
Working Capital	114.35M	125.58M	144.50M	159.23M	78.21M	88.09M	102.19M	119.05M	75.25M	88.08M	95.45M	99.71M
Leverage & Debt
Debt to Equity	0.07	0.08	0.08	0.08	0.15	0.12	0.09	0.10	0.24	0.11	0.09	0.06
Debt Ratio	0.07	0.08	0.07	0.08	0.13	0.11	0.08	0.09	0.19	0.10	0.08	0.06
Efficiency & Turnover
Asset Turnover TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Per Share Metrics
Diluted EPS TTM	-0.78	-0.81	-0.75	-0.98	-1.04	-1.02	-0.99	-1.33	-1.15	-1.11	-1.10	-1.01
Free Cash Flow Per Share TTM	-0.71	-0.74	-0.68	-0.91	-0.94	-0.91	-0.90	-1.11	-0.99	-1.03	-0.93	-0.87
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Growth Metrics
Net Income Growth (1Y)	11.63%	18.41%	11.36%	8.70%	25.40%	25.16%	22.72%	32.19%	20.07%	29.11%	31.18%	26.13%
EPS Growth (1Y)	-24.86%	-20.13%	-24.91%	-26.39%	-9.01%	-8.00%	-9.53%	31.48%	21.48%	29.12%	28.93%	-55.16%
Valuation Metrics
P/E TTM	-3.89	-2.91	-12.60	-4.56	-2.78	-4.82	-4.88	-3.23	-2.23	-0.90	-1.20	-1.96
P/B TTM	2.72	1.91	6.61	2.09	2.46	3.44	2.98	1.83	1.83	0.56	0.66	0.87
Market Cap	317.32M	244.70M	972.17M	338.96M	203.09M	342.71M	338.22M	221.30M	129.57M	51.05M	67.86M	101.35M
Enterprise Value	306.09M	232.76M	963.07M	278.85M	188.49M	333.78M	327.75M	177.40M	123.64M	38.54M	59.80M	85.31M
Calculated Values
Free Cash Flow TTM	-73.48M	-77.15M	-70.49M	-69.08M	-65.60M	-63.44M	-62.80M	-57.37M	-50.20M	-53.00M	-47.56M	-44.63M
Net Debt	-11.24M	-11.94M	-9.10M	-60.11M	-14.60M	-8.93M	-10.47M	-43.91M	-5.93M	-12.50M	-8.06M	-16.04M
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
PEG Ratio
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
EV Revenue TTM
EV FCF TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2026-03-30Purchase

Owner: Evans, Daron

Title: CFO

Shares: 10,000

Price/Share: $2.85

Value: $28,500.00

Shares Owned: 414,462

Relationship: Officer

Ownership: Direct

2025-12-16Purchase

Owner: Hogenhuis, Wladimir

Title: -

Shares: 5,650

Price/Share: $1.69

Value: $9,548.50

Shares Owned: 119,675

Relationship: Director

Ownership: Direct

2025-12-16Purchase

Owner: Roberts, Brian Kenneth

Title: Chief Medical Officer

Shares: 28,000

Price/Share: $1.70

Value: $47,600.00

Shares Owned: 308,352

Relationship: Officer

Ownership: Direct

2025-12-15Purchase

Owner: Evans, Daron

Title: CFO

Shares: 40,000

Price/Share: $1.77

Value: $70,800.00

Shares Owned: 415,900

Relationship: Officer

Ownership: Direct

2025-12-15Purchase

Owner: Elam, Nevan C

Title: CEO

Shares: 32,000

Price/Share: $1.59

Value: $50,880.00

Shares Owned: 641,119

Relationship: Director,Officer

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2026-03-30	Evans, Daron	Officer	CFO	Direct	Purchase	10,000	2.85	$28,500.00	414,462	4
2025-12-16	Hogenhuis, Wladimir	Director	-	Direct	Purchase	5,650	1.69	$9,548.50	119,675	4
2025-12-16	Roberts, Brian Kenneth	Officer	Chief Medical Officer	Direct	Purchase	28,000	1.70	$47,600.00	308,352	4
2025-12-15	Evans, Daron	Officer	CFO	Direct	Purchase	40,000	1.77	$70,800.00	415,900	4
2025-12-15	Elam, Nevan C	Director,Officer	CEO	Direct	Purchase	32,000	1.59	$50,880.00	641,119	4
2025-12-15	Karnawat, Sunil Ratilal	Officer	Chief Commercial Officer	Direct	Purchase	12,100	1.61	$19,481.00	71,542	4
2025-12-09	Evans, Daron	Officer	CFO	Direct	Purchase	10,549	5.04	$53,166.96	131,900	4
2025-06-25	Roberts, Brian Kenneth	Officer	Chief Medical Officer	Direct	Purchase	2,500	4.38	$10,950.00	15,500	4
2025-06-24	Evans, Daron	Officer	CFO	Direct	Purchase	5,000	4.05	$20,250.00	268,900	4
2025-06-13	Kreher, Nerissa	Director	-	Direct	Purchase	3,076	3.25	$9,997.00	37,576	4
2025-06-13	Kim, Young-Jin	Director	-	Indirect	Purchase	1,230,769	3.25	$3,999,999.25	8,423,386	4
2025-03-31	Hogenhuis, Wladimir	Director	-	Direct	Purchase	6,758	2.92	$19,733.36	84,025	4
2025-03-27	Elam, Nevan C	Director,Officer	CEO	Direct	Purchase	12,302	2.85	$35,060.70	224,119	4
2025-03-26	Evans, Daron	Officer	CFO	Direct	Purchase	10,000	2.89	$28,900.00	237,900	4
2025-02-18	Hogenhuis, Wladimir	Director	-	Direct	Purchase	10,000	4.70	$47,000.00	77,267	4
2024-12-18	Evans, Daron	Officer	CFO	Direct	Purchase	10,000	4.29	$42,900.00	150,900	4
2024-12-12	Evans, Daron	Officer	CFO	Direct	Purchase	9,000	4.60	$41,400.00	140,900	4
2024-09-24	Hogenhuis, Wladimir	Director	-	Direct	Purchase	4,259	4.70	$20,017.30	41,767	4
2024-06-25	Kim, Young-Jin	Director	-	Indirect	Purchase	1,250,000	4.00	$5,000,000.00	7,192,617	4
2024-06-25	Hogenhuis, Wladimir	Director	-	Direct	Purchase	4,815	4.15	$19,982.25	37,508	4
2024-06-14	Evans, Daron	Officer	CFO	Indirect	Purchase	40,000	4.04	$161,600.00	40,000	4
2024-06-14	Roberts, Brian Kenneth	Officer	Chief Medical Officer	Direct	Purchase	4,300	3.94	$16,942.00	54,352	4
2024-05-29	Evans, Daron	Officer	CFO	Direct	Purchase	451	3.50	$1,578.50	121,351	4
2024-05-24	Evans, Daron	Officer	CFO	Indirect	Purchase	2,942	3.23	$9,502.66	13,000	4
2024-05-23	Roberts, Brian Kenneth	Officer	Chief Medical Officer	Direct	Purchase	7,500	2.70	$20,250.00	50,052	4
2024-03-28	Roberts, Brian Kenneth	Officer	Chief Medical Officer	Indirect	Purchase	500	2.55	$1,275.00	1,076	4
2024-03-15	Evans, Daron	Officer	CFO	Indirect	Purchase	20,000	1.69	$33,800.00	20,000	4
2024-03-14	Roberts, Brian Kenneth	Officer	Chief Medical Officer	Indirect	Purchase	10,000	1.88	$18,800.00	10,000	4
2024-03-08	Evans, Daron	Officer	CFO	Direct	Purchase	50,000	1.93	$96,500.00	120,900	4
2024-03-07	Kim, Young-Jin	Director	-	Direct	Purchase	36,503	1.91	$69,720.73	115,450	4
2024-03-07	Roberts, Brian Kenneth	Officer	Chief Medical Officer	Indirect	Purchase	500	1.85	$925.00	576	4/A
2024-02-26	Elam, Nevan C	Director,Officer	CEO	Direct	Purchase	5,000	1.68	$8,400.00	7,817	4
2024-02-26	Roberts, Brian Kenneth	Officer	Chief Medical Officer	Direct	Purchase	2,000	1.70	$3,400.00	42,552	4
2024-02-16	Roberts, Brian Kenneth	Officer	Chief Medical Officer	Direct	Purchase	7,000	1.31	$9,170.00	34,552	4
2024-02-16	Evans, Daron	Officer	CFO	Direct	Purchase	41,900	1.30	$54,470.00	70,900	4
2023-07-03	Roberts, Brian Kenneth	Officer	Chief Medical Officer	Direct	Purchase	5,000	1.90	$9,500.00	27,552	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Institutional Ownership

No data available for chart

2026-03-31

82.50%

Inst. Shares: 85,831,054

Shares Outstanding: 104,040,292

2025-12-31

86.20%

Inst. Shares: 89,375,422

Shares Outstanding: 103,687,064

2025-09-30

83.98%

Inst. Shares: 86,850,689

Shares Outstanding: 103,422,647

2025-06-30

101.91%

Inst. Shares: 77,447,324

Shares Outstanding: 75,999,290

2025-03-31

63.13%

Inst. Shares: 44,212,588

Shares Outstanding: 70,031,041

Date	Institutional Shares Owned	Shares Outstanding	Institutional Ownership %
2026-03-31	85,831,054	104,040,292	82.50%
2025-12-31	89,375,422	103,687,064	86.20%
2025-09-30	86,850,689	103,422,647	83.98%
2025-06-30	77,447,324	75,999,290	101.91%
2025-03-31	44,212,588	70,031,041	63.13%
2024-12-31	42,506,417	69,940,319	60.78%
2024-09-30	38,153,869	69,736,150	54.71%
2024-06-30	39,315,089	51,466,150	76.39%
2024-03-31	26,608,219	50,812,332	52.37%
2023-12-31	28,900,926	51,408,000	56.22%
2023-09-30	23,863,827	51,409,000	46.42%
2023-06-30	24,202,264	51,187,000	47.28%
Additional institutional holders are for subscribers only. Unlock the complete Form 13F ownership history Start 7-day free trial

Rezolute, Inc. (RZLT) — SEC Financial Statements & Analysis

Rezolute, Inc. (RZLT) is a pharmaceutical preparations company, incorporated in NV. Rezolute, Inc. trades on Nasdaq as: RZLT. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Rezolute, Inc. reported a Debt-to-Equity ratio of 0.07x, a Price-to-Book (P/B) ratio of 2.72x (TTM), at a market cap of $317.32M. Figures below are sourced from SEC EDGAR, as-filed.

Debt To Equity: 0.07x
P/B TTM: 2.72x
Market Cap: $317.32M

Data as of 2026-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Rezolute, Inc. in?

Rezolute, Inc. (RZLT) operates in the Pharmaceutical Preparations industry.

What is RZLT's market cap?

Rezolute, Inc. (RZLT) has a market capitalization of $317.32M as of 2026-03-31.

What exchange does RZLT trade on?

Rezolute, Inc. (RZLT) trades on the Nasdaq.

Where is Rezolute, Inc. incorporated?

Rezolute, Inc. is incorporated in NV.

Rezolute, Inc.

Financial Statements

Custom Table

Interactive Financial Visualizations

Earnings Market Reaction

Performance and Valuation Metrics

Insider Transactions

Institutional Ownership

Rezolute, Inc. (RZLT) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.
Main Street's price.

Rezolute, Inc. (RZLT) — SEC Financial Statements & Analysis

Frequently Asked Questions

Companies in Pharmaceutical Preparations

Wall Street's data.Main Street's price.

Wall Street's data.
Main Street's price.